Cargando…
Impact on clinical practice of updated guidelines on iodinated contrast material: CINART
OBJECTIVE: Guidelines on safe use of iodinated contrast material recommend intravenous prophylactic hydration to prevent post-contrast adverse (renal) effects. Recently, guidelines have been updated and standard prophylaxis is no longer recommended for the majority of patients. The current study aim...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305084/ https://www.ncbi.nlm.nih.gov/pubmed/32107605 http://dx.doi.org/10.1007/s00330-020-06719-7 |
_version_ | 1783548384027607040 |
---|---|
author | Nijssen, E. C. Nelemans, P. J. Rennenberg, R. J. van der Molen, A. J. van Ommen, G. V. Wildberger, J. E. |
author_facet | Nijssen, E. C. Nelemans, P. J. Rennenberg, R. J. van der Molen, A. J. van Ommen, G. V. Wildberger, J. E. |
author_sort | Nijssen, E. C. |
collection | PubMed |
description | OBJECTIVE: Guidelines on safe use of iodinated contrast material recommend intravenous prophylactic hydration to prevent post-contrast adverse (renal) effects. Recently, guidelines have been updated and standard prophylaxis is no longer recommended for the majority of patients. The current study aims to evaluate the consequences for clinical practice of the updated guidelines in terms of complications, hospitalisations, and costs. METHODS: The Contrast-Induced Nephropathy After Reduction of the prophylaxis Threshold (CINART) project is a retrospective observational study. All elective procedures with intravascular iodinated contrast administration at Maastricht University Medical Centre (UMC+) in patients aged > 18 years, formerly eligible for prophylaxis (eGFR 30–44 ml/min/1.73 m(2) or eGFR 45–59 ml/min/1.73 m(2) in combination with diabetes or > 1 predefined risk factor), and currently eligible for prophylaxis (eGFR < 30 ml/min/1.73 m(2)) were included. Data were used to calculate relative reductions in complications, hospitalisations, and costs associated with standard prophylactic intravenous hydration. CINART is registered with Clinicaltrials.gov: NCT03227835. RESULTS: Between July 1, 2017, and July 1, 2018, 1992 elective procedures with intravascular iodinated contrast in patients formerly and currently eligible for prophylaxis were identified: 1808 in patients formerly eligible for prophylaxis and 184 in patients currently eligible for prophylaxis. At Maastricht UMC+, guideline updates led to large relative reductions in numbers of complications of prophylaxis (e.g. symptomatic heart failure; − 89%), extra hospitalisations (− 93%), and costs (− 91%). CONCLUSION: Guideline updates have had a demonstrable impact on daily clinical practice benefiting patient, hospital, and health care budgets. Clinical practice varies between institutions and countries; therefore, a local estimation model is provided with which local impact on costs, hospitalisations, and complications can be calculated. KEY POINTS: • Clinical practice guidelines recommend prophylactic intravenous hydration to prevent post-contrast adverse outcomes such as contrast-induced acute kidney injury. • Clinical practice guidelines have recently been updated, and standard prophylaxis is no longer recommended for the majority of patients. • The guideline updates have a large impact on daily clinical practice: relative reductions at Maastricht UMC+ were − 89% prophylaxis complications, − 93% hospitalisations, and − 91% costs, and similar reductions are expected for Dutch and adherent European medical centres. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00330-020-06719-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7305084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-73050842020-06-22 Impact on clinical practice of updated guidelines on iodinated contrast material: CINART Nijssen, E. C. Nelemans, P. J. Rennenberg, R. J. van der Molen, A. J. van Ommen, G. V. Wildberger, J. E. Eur Radiol Contrast Media OBJECTIVE: Guidelines on safe use of iodinated contrast material recommend intravenous prophylactic hydration to prevent post-contrast adverse (renal) effects. Recently, guidelines have been updated and standard prophylaxis is no longer recommended for the majority of patients. The current study aims to evaluate the consequences for clinical practice of the updated guidelines in terms of complications, hospitalisations, and costs. METHODS: The Contrast-Induced Nephropathy After Reduction of the prophylaxis Threshold (CINART) project is a retrospective observational study. All elective procedures with intravascular iodinated contrast administration at Maastricht University Medical Centre (UMC+) in patients aged > 18 years, formerly eligible for prophylaxis (eGFR 30–44 ml/min/1.73 m(2) or eGFR 45–59 ml/min/1.73 m(2) in combination with diabetes or > 1 predefined risk factor), and currently eligible for prophylaxis (eGFR < 30 ml/min/1.73 m(2)) were included. Data were used to calculate relative reductions in complications, hospitalisations, and costs associated with standard prophylactic intravenous hydration. CINART is registered with Clinicaltrials.gov: NCT03227835. RESULTS: Between July 1, 2017, and July 1, 2018, 1992 elective procedures with intravascular iodinated contrast in patients formerly and currently eligible for prophylaxis were identified: 1808 in patients formerly eligible for prophylaxis and 184 in patients currently eligible for prophylaxis. At Maastricht UMC+, guideline updates led to large relative reductions in numbers of complications of prophylaxis (e.g. symptomatic heart failure; − 89%), extra hospitalisations (− 93%), and costs (− 91%). CONCLUSION: Guideline updates have had a demonstrable impact on daily clinical practice benefiting patient, hospital, and health care budgets. Clinical practice varies between institutions and countries; therefore, a local estimation model is provided with which local impact on costs, hospitalisations, and complications can be calculated. KEY POINTS: • Clinical practice guidelines recommend prophylactic intravenous hydration to prevent post-contrast adverse outcomes such as contrast-induced acute kidney injury. • Clinical practice guidelines have recently been updated, and standard prophylaxis is no longer recommended for the majority of patients. • The guideline updates have a large impact on daily clinical practice: relative reductions at Maastricht UMC+ were − 89% prophylaxis complications, − 93% hospitalisations, and − 91% costs, and similar reductions are expected for Dutch and adherent European medical centres. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00330-020-06719-7) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-02-27 2020 /pmc/articles/PMC7305084/ /pubmed/32107605 http://dx.doi.org/10.1007/s00330-020-06719-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Contrast Media Nijssen, E. C. Nelemans, P. J. Rennenberg, R. J. van der Molen, A. J. van Ommen, G. V. Wildberger, J. E. Impact on clinical practice of updated guidelines on iodinated contrast material: CINART |
title | Impact on clinical practice of updated guidelines on iodinated contrast material: CINART |
title_full | Impact on clinical practice of updated guidelines on iodinated contrast material: CINART |
title_fullStr | Impact on clinical practice of updated guidelines on iodinated contrast material: CINART |
title_full_unstemmed | Impact on clinical practice of updated guidelines on iodinated contrast material: CINART |
title_short | Impact on clinical practice of updated guidelines on iodinated contrast material: CINART |
title_sort | impact on clinical practice of updated guidelines on iodinated contrast material: cinart |
topic | Contrast Media |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305084/ https://www.ncbi.nlm.nih.gov/pubmed/32107605 http://dx.doi.org/10.1007/s00330-020-06719-7 |
work_keys_str_mv | AT nijssenec impactonclinicalpracticeofupdatedguidelinesoniodinatedcontrastmaterialcinart AT nelemanspj impactonclinicalpracticeofupdatedguidelinesoniodinatedcontrastmaterialcinart AT rennenbergrj impactonclinicalpracticeofupdatedguidelinesoniodinatedcontrastmaterialcinart AT vandermolenaj impactonclinicalpracticeofupdatedguidelinesoniodinatedcontrastmaterialcinart AT vanommengv impactonclinicalpracticeofupdatedguidelinesoniodinatedcontrastmaterialcinart AT wildbergerje impactonclinicalpracticeofupdatedguidelinesoniodinatedcontrastmaterialcinart |